Pediatric obesity has reached epidemic proportions in the United States — 20% of children and adolescents aged 2–19 meet the BMI ≥95th percentile definition of obesity, with severe obesity (BMI ≥120% of the 95th percentile) now affecting 6% of children. The AAP published a landmark Clinical Practice Guideline in 2023 that fundamentally shifted the paradigm of pediatric obesity management — acknowledging the chronic disease nature of obesity, rejecting "watchful waiting" approaches, and explicitly endorsing intensive interventions including pharmacotherapy and bariatric surgery for appropriate patients. This guide reviews the current clinical evidence and management recommendations. Pediatric clinical supplies supporting assessment and management programs are available in our pediatric catalog and diagnostic equipment section.
The 2023 AAP CPG: A Paradigm Shift
The 2023 AAP Clinical Practice Guideline for Evaluation and Treatment of Children and Adolescents with Obesity made several landmark recommendations: (1) Intensive Health Behavior and Lifestyle Treatment (IHBLT) — at least 26 hours over 3–12 months, covering dietary education, physical activity promotion, and behavioral counseling — as first-line treatment for all children with obesity over age 6; "watchful waiting" or "brief counseling" are explicitly rejected as ineffective; (2) Pharmacotherapy for adolescents ≥12 with BMI ≥95th percentile — orlistat and phentermine/topiramate (FDA-approved) and off-label metformin are endorsed; (3) Bariatric surgery evaluation for adolescents ≥13 (girls) or ≥15 (boys) with BMI ≥120% of the 95th percentile, particularly with severe comorbidities — reflecting evidence that surgical outcomes in adolescents are equivalent to adults with better long-term cardiometabolic remission. The guideline acknowledges the "obesity stigma" challenge — clinician attitudes toward children with obesity significantly impact outcomes.
Semaglutide in Pediatric Obesity
The STEP TEENS RCT (2022, NEJM) demonstrated semaglutide 2.4mg weekly produced 16.1% mean body weight reduction vs 0.6% in placebo over 68 weeks in adolescents aged 12–17 with BMI ≥30 kg/m² — comparable to adult outcomes and unprecedented for any pharmacotherapy in this population. FDA approved semaglutide for obesity in adolescents ≥12 in December 2022 (Wegovy). Nutritional monitoring during GLP-1 therapy in adolescents is particularly important given growth requirements — protein adequacy (supporting linear growth and lean mass) and micronutrient monitoring are essential clinical components of pediatric GLP-1 programs. Our clinical nutrition catalog and pediatric supplies section support comprehensive pediatric obesity management programs.
